The purpose of this study is to determine the efficacy and safety of a routine individualized antiplatelet therapy after coronary stent implantation by evaluating "on-treatment" platelet reactivity with Multiple Electrode Aggregometry (MEA, Multiplate® Analyzer). IDEAL-PCI Extended is the continuation of the IDEAL-PCI registry with additional focus on bleeding events and net clinical benefit
Determination of platelet reactivity in patients with percutaneous coronary Intervention as described in the IDEAL-PCI registry. In the IDEAL-PCI Extended Registry an additional deescalation arm with reduction of the standard dual antiplatelet therapy (DAPT) dosis in case of low platelet reactivity to P2Y12 Inhibition or Aspirin with or without bleeding is implemented.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Reduction of standard dose DAPT due to low platelet reactivity
Standard DAPT within the therapeutic window of platelet reactivity
Intensification of standard dose DAPT due to high platelet reactivity
Kaiser Franz Josef Hospital
Vienna, Austria
stent thrombosis
stent thrombosis by any Academic Research Consortium (ARC) definition
Time frame: 1 year
bleeding
bleeding type 1-3 and 5 by Bleeding Academic Research Consortium (BARC) definition
Time frame: 1 year
Major adverse cardiac and cerebrovascular Events (MACCE)
death, cardiovascular death, myocardial infarction, stroke, ischemia driven revascularization
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.